Lung Cancer

Dr. Nabil Rizk, chief of thoracic surgery at Hackensack University Medical Center, explains that segmentectomy is “just a little bit more of a refined way of treating cancers.”

Diane Messick, a three-time lung cancer survivor, tells CURE® about her cancer journey which has included a segmentectomy, a lobectomy and radiation treatment since receiving her first diagnosis in 2017.

Every individual is unique in their own way.

As part of its Speaking Out® video series, CURE® spoke Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, about advancements in treating non-small cell lung cancer and the unmet needs that persist for patients.

As part of its Speaking Out® video series, CURE® spoke with Kimberly Buchmeier, a lung cancer survivor and board member of LiveLung.

The Food and Drug Administration approved six new cancer therapies in November 2023.

Datopotamab deruxtecan elicited encouraging responses in patients with heavily pretreated non–small cell lung cancer harboring actionable genomic alterations.

Immune checkpoint inhibitors and stereotactic radiosurgery do not increase the risk of necrosis among patients with NSCLC who have brain metastases, according to research.

New research revealed that genetic information near healthy tissue surrounding lung tumors may have a better change of determining recurrence in patients with lung cancer.

The Food and Drug Administration approved Augtyro for patients with ROS1-positive metastatic non-small cell lung cancer based on a phase 1/2 trial.

CURE® highlights some of the most significant lung cancer news of 2023 in honor of Lung Cancer Awareness Month.

This November, our country celebrates 76 years of Veteran’s Day, and we want to increase awareness of veterans with lung cancer in this special issue of CURE.

Dr. Gene G. Finley spoke about current patient treatment obstacles as part of CURE’s ‘Speaking Out’ video series.

U.S. veterans face exposures during military service and disparities at home.

Friendship means the world throughout a cancer experience.

Managing side effects from lung cancer treatment with dose reductions is an approach experts have been using more, even though some patients voice concerns about lowering a drug’s impact on the disease.

Patients with extensive-stage small cell lung cancer responded well to the treatment of Trodelvy, according to preliminary results from a phase 2 trial.

Two phase 3 randomized trials focused on evaluating the safety and efficiency of anamorelin to treat adult patients with advanced non-small cell lung cancer linked with weight loss and cachexia.

Dear every oncology team...

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, explains why the approval of Braftovi and Mektovi “It's an important improvement in our armamentarium.”

I had to redefine the relationship with my mother during the most challenging of times.

Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.

The treatment combination of Rybrevant plus chemotherapy offers better progression-free survival for patients with advanced EGFR exon 20 insertion-positive NSCLC.

Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.

Patients with ALK-positive, early-stage non-small cell lung cancer obtained significant improvement in disease-free survival.

Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.

Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.

Patients with previously treated small cell lung cancer who received a 10-mg dose of tarlatamab had improved responses with no new safety signals.

As Susan Sullivan discussed her lung cancer diagnosis and the FDA discusses banning specific hair straightening products due to long-term health effects, here’s what’s happening in the oncology space this week.